

The Evaluation Advisory Committee (EAC) Report

Quality assessment of the evaluation

Name of evaluation: COVAX Facility and COVAX Advance Market Commitment (AMC)
Formative Review and Baseline Study

Year of report: 2023

a) The Evaluation Advisory Committee (EAC) rated this report as;

- ☒ Fully met or exceeded Gavi quality standards
- ☐ Met Gavi quality standards with only minor shortcomings
- ☐ Partially met Gavi quality standards with some shortcomings
- ☐ Did not meet Gavi quality standards with major shortcomings

b) General comments:

Strengths

The report is well structured and clearly written with appropriate use of annexes. The purpose, scope and objectives are well outlined. The evaluation design and methods are adequately described. The Executive Summary is clear. Findings, lessons learned, conclusions and recommendations are, overall, well supported by evidence.

Shortcomings

While the report is clearly written and appropriate for the primary target audiences, it may not be accessible to all potential audiences as the language includes technical aspects that require prior knowledge to understand. The wider contextual factors are not fully explored. The addition of a rationale for the methodology and a section on ethical considerations would have been helpful. Recommendations could be better targeted.